Korea's Ildong Pharmaceutical In Licensing Deal With Taiwan Liposome Firm To Sell Product In Korean Market
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ildong Pharmaceutical has signed a marketing and distribution agreement with Taiwan Liposome Company to sell the latter's arterial vasodilator and platelet-aggregation inhibitor ProFlow (alprostadil) - available as a generic - in Korea
You may also be interested in...
South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment
SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Taiwan Liposome Company Nearing IPO After Round Of Financing
HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering